Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...
Morningstar3d
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Additionally, we are advancing an autologous, gene-edited CAR T therapy targeting glypican-3 ... the erythroid specific enhancer region of the BCL11A gene. This edit results in the production ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
pharmaphorum2d
ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disorders
The trials are the first to test a CRISPR/Cas9 gene editing therapy in humans for a genetic ... by introducing a gene known as BCL11A which down-regulates the production of the adult form of ...
precisionmedicineonline1d
Precision Medicine Supporters Worry About NIH Indirect Rate Cut's Impact on Advances, Workforce
Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...